Report Cover

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Growth 2020-2025


According to this study, over the next five years the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, covering the supply chain analysis, impact assessment to the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size growth rate in several scenarios, and the measures to be undertaken by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
    Eluxadoline
    Alosetron
    Rifaximin
    Loperamide
    Diphenoxylate + Atropine
    Dicyclomine and Hyoscyamine

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
    Hospitals
    Clinics
    Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
    Astellas Pharmaceuticals
    Actavis
    GlaxoSmithKline
    Salix Pharmaceuticals Ltd
    Pfizer
    AstraZenenca
    ...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
    To study and analyze the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
    To understand the structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by identifying its various subsegments.
    Focuses on the key global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    To project the consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
    1.1 Market Introduction
    1.2 Research Objectives
    1.3 Years Considered
    1.4 Market Research Methodology
    1.5 Data Source
    1.6 Economic Indicators
    1.7 Currency Considered

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2025
        2.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption CAGR by Region
    2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
        2.2.1 Eluxadoline
        2.2.2 Alosetron
        2.2.3 Rifaximin
        2.2.4 Loperamide
        2.2.5 Diphenoxylate + Atropine
        2.2.6 Dicyclomine and Hyoscyamine
    2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
        2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
        2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2015-2020)
        2.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2015-2020)
    2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
        2.4.1 Hospitals
        2.4.2 Clinics
        2.4.3 Others
    2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
        2.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
        2.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value and Market Share by Type (2015-2020)
        2.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2015-2020)

3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company
    3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company
        3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2018-2020)
        3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2018-2020)
    3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company
        3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2018-2020)
        3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2018-2020)
    3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company
    3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution, Sales Area, Type by Company
        3.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution and Sales Area by Company
        3.4.2 Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
    3.6 New Products and Potential Entrants
    3.7 Mergers & Acquisitions, Expansion

4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
    4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
    4.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth
    4.3 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth
    4.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth
    4.5 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth

5 Americas
    5.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
        5.1.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020)
        5.1.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020)
    5.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
    5.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil
    5.8 Key Economic Indicators of Few Americas Countries

6 APAC
    6.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Regions
        6.1.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Regions (2015-2020)
        6.1.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Regions (2015-2020)
    6.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
    6.3 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
    7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
        7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020)
        7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020)
    7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
    7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia
    7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
    8.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
        8.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020)
        8.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020)
    8.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
    8.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers and Impact
        9.1.1 Growing Demand from Key Regions
        9.1.2 Growing Demand from Key Applications and Potential Industries
    9.2 Market Challenges and Impact
    9.3 Market Trends

10 Marketing, Distributors and Customer
    10.1 Sales Channel
        10.1.1 Direct Channels
        10.1.2 Indirect Channels
    10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
    10.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer

11 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast
    11.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2021-2025)
    11.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Regions
        11.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Regions (2021-2025)
        11.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Regions (2021-2025)
        11.2.3 Americas Consumption Forecast
        11.2.4 APAC Consumption Forecast
        11.2.5 Europe Consumption Forecast
        11.2.6 Middle East & Africa Consumption Forecast
    11.3 Americas Forecast by Countries
        11.3.1 United States Market Forecast
        11.3.2 Canada Market Forecast
        11.3.3 Mexico Market Forecast
        11.3.4 Brazil Market Forecast
   11.4 APAC Forecast by Countries
        11.4.1 China Market Forecast
        11.4.2 Japan Market Forecast
        11.4.3 Korea Market Forecast
        11.4.4 Southeast Asia Market Forecast
        11.4.5 India Market Forecast
        11.4.6 Australia Market Forecast
    11.5 Europe Forecast by Countries
        11.5.1 Germany Market Forecast
        11.5.2 France Market Forecast
        11.5.3 UK Market Forecast
        11.5.4 Italy Market Forecast
        11.5.5 Russia Market Forecast
    11.6 Middle East & Africa Forecast by Countries
        11.6.1 Egypt Market Forecast
        11.6.2 South Africa Market Forecast
        11.6.3 Israel Market Forecast
        11.6.4 Turkey Market Forecast
        11.6.5 GCC Countries Market Forecast
    11.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Type
    11.8 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Application

12 Key Players Analysis
    12.1 Astellas Pharmaceuticals
        12.1.1 Company Information
        12.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
        12.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
        12.1.4 Main Business Overview
        12.1.5 Astellas Pharmaceuticals Latest Developments
    12.2 Actavis
        12.2.1 Company Information
        12.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
        12.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
        12.2.4 Main Business Overview
        12.2.5 Actavis Latest Developments
    12.3 GlaxoSmithKline
        12.3.1 Company Information
        12.3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
        12.3.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
        12.3.4 Main Business Overview
        12.3.5 GlaxoSmithKline Latest Developments
    12.4 Salix Pharmaceuticals Ltd
        12.4.1 Company Information
        12.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
        12.4.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
        12.4.4 Main Business Overview
        12.4.5 Salix Pharmaceuticals Ltd Latest Developments
    12.5 Pfizer
        12.5.1 Company Information
        12.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
        12.5.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
        12.5.4 Main Business Overview
        12.5.5 Pfizer Latest Developments
    12.6 AstraZenenca
        12.6.1 Company Information
        12.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
        12.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
        12.6.4 Main Business Overview
        12.6.5 AstraZenenca Latest Developments
    ...

13 Research Findings and Conclusion

List of Tables Table 1. Research Methodology Table 2. Data Source Table 3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption CAGR by Region 2015-2025 ($ Millions) Table 4. Major Players of Eluxadoline Table 5. Major Players of Alosetron Table 6. Major Players of Rifaximin Table 7. Major Players of Loperamide Table 8. Major Players of Diphenoxylate + Atropine Table 9. Major Players of Dicyclomine and Hyoscyamine Table 10. Global Consumption Sales by Type (2015-2020) Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020) Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2015-2020) ($ million) Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Type (2015-2020) ($ Millions) Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2015-2020) Table 15. Global Consumption Sales by Application (2015-2020) Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020) Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Application (2015-2020) Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Application (2015-2020) Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Application (2015-2020) Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2017-2019) (K MT) Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2017-2019) Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2017-2019) ($ Millions) Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2017-2019) Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company (2017-2019) Table 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution and Sales Area by Manufacturers Table 26. Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered Table 27. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019) Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Regions 2015-2020 (K MT) Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Regions 2015-2020 Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Regions 2015-2020 ($ Millions) Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions 2015-2020 Table 32. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT) Table 33. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020) Table 34. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020) ($ Millions) Table 35. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries (2015-2020) Table 36. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT) Table 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020) Table 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT) Table 39. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020) Table 40. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT) Table 41. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020) Table 42. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Regions (2015-2020) ($ Millions) Table 43. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions (2015-2020) Table 44. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT) Table 45. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020) Table 46. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT) Table 47. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020) Table 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT) Table 49. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020) Table 50. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020) ($ Millions) Table 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries (2015-2020) Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT) Table 53. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020) Table 54. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT) Table 55. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020) Table 56. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT) Table 57. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020) Table 58. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020) ($ Millions) Table 59. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries (2015-2020) Table 60. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT) Table 61. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020) Table 62. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT) Table 63. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020) Table 64. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List Table 65. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer List Table 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Countries (2021-2025) (K MT) Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Forecast by Regions Table 68. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Countries (2021-2025) ($ Millions) Table 69. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share Forecast by Regions Table 70. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Type (2021-2025) (K MT) Table 71. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share Forecast by Type (2021-2025) Table 72. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Type (2021-2025) ($ Millions) Table 73. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share Forecast by Type (2021-2025) Table 74. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Application (2021-2025) (K MT) Table 75. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share Forecast by Application (2021-2025) Table 76. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Application (2021-2025) ($ Millions) Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share Forecast by Application (2021-2025) Table 78. Astellas Pharmaceuticals Product Offered Table 79. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E) Table 80. Astellas Pharmaceuticals Main Business Table 81. Astellas Pharmaceuticals Latest Developments Table 82. Astellas Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors Table 83. Actavis Product Offered Table 84. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E) Table 85. Actavis Main Business Table 86. Actavis Latest Developments Table 87. Actavis Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors Table 88. GlaxoSmithKline Product Offered Table 89. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E) Table 90. GlaxoSmithKline Main Business Table 91. GlaxoSmithKline Latest Developments Table 92. GlaxoSmithKline Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors Table 93. Salix Pharmaceuticals Ltd Product Offered Table 94. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E) Table 95. Salix Pharmaceuticals Ltd Main Business Table 96. Salix Pharmaceuticals Ltd Latest Developments Table 97. Salix Pharmaceuticals Ltd Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors Table 98. Pfizer Product Offered Table 99. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E) Table 100. Pfizer Main Business Table 101. Pfizer Latest Developments Table 102. Pfizer Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors Table 103. AstraZenenca Product Offered Table 104. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E) Table 105. AstraZenenca Main Business Table 106. AstraZenenca Latest Developments Table 107. AstraZenenca Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors List of Figures Figure 1. Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Figure 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered Figure 3. Market Research Methodology Figure 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth Rate 2015-2025 (K MT) Figure 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth Rate 2015-2025 ($ Millions) Figure 6. Product Picture of Eluxadoline Figure 7. Product Picture of Alosetron Figure 8. Product Picture of Rifaximin Figure 9. Product Picture of Loperamide Figure 10. Product Picture of Diphenoxylate + Atropine Figure 11. Product Picture of Dicyclomine and Hyoscyamine Figure 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020) Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Type (2015-2020) Figure 14. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Hospitals Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Hospitals (2015-2020) (K MT) Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Hospitals (2015-2020) ($ Millions) Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Clinics Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Clinics (2015-2020) (K MT) Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Clinics (2015-2020) ($ Millions) Figure 20. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Others Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Others (2015-2020) (K MT) Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Others (2015-2020) ($ Millions) Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020) Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Application (2015-2020) Figure 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company in 2017 Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company in 2019 Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company in 2017 Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company in 2019 Figure 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company in 2019 Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Regions 2015-2020 Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions 2015-2020 Figure 32. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT) Figure 33. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions) Figure 34. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT) Figure 35. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions) Figure 36. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT) Figure 37. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions) Figure 38. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT) Figure 39. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions) Figure 40. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019 Figure 41. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries in 2019 Figure 42. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019 Figure 43. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019 Figure 44. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 45. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 46. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 47. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 48. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 49. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 50. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019 Figure 51. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions in 2019 Figure 52. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019 Figure 53. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019 Figure 54. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 55. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 56. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 57. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 58. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 59. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 60. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 61. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 62. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 63. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 64. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 65. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 66. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019 Figure 67. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries in 2019 Figure 68. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019 Figure 69. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019 Figure 70. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 71. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 72. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 73. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 74. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 75. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 76. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 77. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 78. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 79. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 80. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019 Figure 81. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries in 2019 Figure 82. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019 Figure 83. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019 Figure 84. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 85. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 86. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 87. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 88. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 89. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 90. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 91. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 92. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT) Figure 93. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions) Figure 94. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth Rate Forecast (2021-2025) (K MT) Figure 95. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth Rate Forecast (2021-2025) ($ Millions) Figure 96. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 97. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 98. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 99. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 100. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 101. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 102. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 103. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 104. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 105. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 106. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 107. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 108. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 109. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 110. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 111. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 112. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 113. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 114. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 115. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 116. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 117. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 118. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 119. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 120. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 121. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 122. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 123. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 124. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 125. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 126. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 127. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 128. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 129. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 130. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 131. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 132. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 133. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 134. Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 135. Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 136. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 137. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 138. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 139. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 140. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 141. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 142. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 143. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 144. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT) Figure 145. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions) Figure 146. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020) Figure 147. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020) Figure 148. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020) Figure 149. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020) Figure 150. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020) Figure 151. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020)

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

New Pharmaceuticals and Healthcare Reports

Internal Neuromodulation Market Forecast 2025 | Global Report

Rising number of patients suffering from neurological disorders such as Parkinson’s, essential tremor, and primary dystonia is fueling the demand for internal neuromodulation procedures. Chronic back and leg pain associated with PVD (peripheral...

Gastrointestinal Cancer Treatment Market Size 2020-2025 | Growth Forecasts

As per credible projections, gastrointestinal cancer treatment industry is expected to register strong CAGR over 2019-2025. Rising adoption of unhealthy eating habits and increasing consumption of tobacco and alcohol have increased the pervasiveness ...

Topotecan Hydrochloride Market Trends and Research Insights by 2025

As per credible estimates, global topotecan hydrochloride market is poised to acquire commendable gains by the year 2025. Rising adoption of unhealthy and sedentary lifestyle has increased the pervasiveness of small cell lung cancer, ovarian cancer, ...

Flu Vaccine Market Share 2020-2025 | Global Industry Report

As per trusted estimates, global flu vaccine market will record substantial growth during 2020-2025. Increasing government initiatives to ensure the safety of the populace, minimal side-effects associated with influenza vaccines, improving efficacy o...

Healthcare Linen Market Size - Industry Trends Report 2025

According to reliable projections, global healthcare linen market is projected to record considerable growth during 2020-2025. Rising prevalence of various diseases including cardiovascular diseases, cancer, and arthritis along with increasing cases ...

Other Reports by LP Information Inc

Global Bluetooth Car Speakers Market Growth 2020-2025

According to this study, over the next five years the Bluetooth Car Speakers market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents ...

Global Audio Drivers Market Growth (Status and Outlook) 2020-2025

According to this study, over the next five years the Audio Drivers market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the glob...

Global Bluetooth Speakers Market Growth 2020-2025

According to this study, over the next five years the Bluetooth Speakers market will register a 2.9%% CAGR in terms of revenue, the global market size will reach $ 5543.3 million by 2025, from $ 4937.5 million in 2019. In particular, this report pres...

Global Multimedia Speakers Market Growth 2020-2025

According to this study, over the next five years the Multimedia Speakers market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the...

Global Wind Power Lubricating Grease Market Growth 2020-2025

According to this study, over the next five years the Wind Power Lubricating Grease market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report pr...

Publisher: LP Information Inc
Chat with us